#NEWS: Novavax completes U.S. marketing authorization transfer to @Sanofi for Nuvaxovid™, following the EU transfer in October in line with its collaboration and license agreement as well as its corporate strategy. https://t.co/Sij8kSkPka

#NEWS: Novavax executes planned site consolidation, further reducing cost footprint in line with our corporate strategy. Learn more: https://t.co/OlLJojTJSZ

This #HealthLiteracyMonth, we’re sharing accessible information on vaccines to empower people to make informed health decisions. Building #HealthLiteracy is essential to address uncertainties, strengthen confidence and ultimately improve global health. Watch to learn more.

#NEWS: Novavax continues to deliver on @Sanofi partnership, completing Nuvaxovid® EU marketing authorization transfer. https://t.co/QKmi2lyfBi

Novavax has further deepened its partnership with Sanofi, announcing an expansion of Sanofi’s license to include the use of Matrix-M® adjuvant in Sanofi’s pandemic influenza vaccine candidate program, supported by recent BARDA funding. Read more: https://t.co/Z6HA7h9b6o

#NEWS: Our COVID-19 vaccine is now approved in Japan for individuals aged 6 and older. Learn more: https://t.co/2ZPAJgSfPW

The 2025-2026 formulation of our COVID-19 vaccine is approved for use in individuals 65 years and older, or 12 years through 64 years of age with at least one underlying condition that puts them at high risk for severe outcomes from COVID-19. https://t.co/4sWRbrtH0U

#NEWS: Novavax announced the U.S. Food and Drug Administration (@FDA) has approved the Company’s Biologics License Application for its COVID-19 vaccine, Nuvaxovid™, triggering a Sanofi milestone payment. Read the news release: https://t.co/QqGXrhfT3Q

#Statement: Novavax responded to the formal communication request for a postmarketing commitment received from the U.S. Food and Drug Administration (FDA) for our Biologics License Application (BLA). Read more: https://t.co/ljdQVSTWj3

#Statement: We have received formal communication from the U.S. Food and Drug Administration (FDA) about the Novavax COVID-19 vaccine Biologics License Application (BLA). Read more: https://t.co/f8asua3zuQ

At this year’s #ESCMID Congress, we presented new real-world data from the SHIELD-Utah study conducted in partnership with the University of Utah Health Read more about the findings: https://t.co/OjtNtVHwl7

An update on the status of Novavax’s COVID-19 Vaccine BLA

We have a clear corporate growth strategy and many near-term milestones to look forward to in 2025. Read more: https://t.co/pp3pS3doDX

We are focused on driving vaccine innovation to tackle global health challenges and create value for ​ our stakeholders through R&D and additional partnerships. Read more: https://t.co/OMgtH6ASmV

Novavax’s corporate growth strategy includes four core value drivers: 🔷 Executing on current partnerships 🔷 Advancing our late-stage pipeline 🔷 Driving additional partnerships and deals through our technology 🔷 Building a robust early-stage pipeline. Learn more:

We are excited to be in San Francisco this week and share how Novavax is executing against our new corporate growth strategy, focused on delivering value through R&D and partnerships.  To learn more about how we’re reshaping our future, click here: https://t.co/1SXSNB23w3

We’re excited to be in San Francisco this week having meaningful conversations and sharing our vision for our new corporate growth strategy.  Key to this is our  technology platform. When combined with our deep vaccine expertise, it fuels innovation and partnerships that can

We’re excited to share more about our corporate strategy and how we’re focused on harnessing the promise of vaccine innovation to improve global health. Read more about our new approach to R&D and strategic partnerships in this article https://t.co/0MQ0cTc6DJ and our presentation

Our science has been featured in several new publications. Learn more about our research: https://t.co/Ur8lnOxQpo #MedicalProfessionals #ScientificCommunity